<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893854</url>
  </required_header>
  <id_info>
    <org_study_id>8727</org_study_id>
    <nct_id>NCT00893854</nct_id>
  </id_info>
  <brief_title>The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema</brief_title>
  <official_title>The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis.
      The treatment for reducing the intra-ocular inflammation can decrease the macular edema. In
      some patients, CME persists even after inflammation control, and additional treatment is
      needed for better vision. Oral steroid, periocular and intravitreal Triamcinolone are the
      principles in treatment, but some complications like cataracts and increased ocular pressure
      have been seen. Diclophenac is a non-steroid anti-inflammatory drug that improves the vision
      and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in
      vascular endothelial growth factor (VEGF) inhibition. In this study, the investigators are
      going to compare the therapeutic affect of intravitreal Diclophenac and Triamcinolone in
      persistent uveitic cystoids macular edema. Since diclophenac is a cheap and accessible drug
      in all curative centers it could be applied instead of Triamcinolone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <condition>Uveitis</condition>
  <condition>Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Diclophenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclophenac</intervention_name>
    <arm_group_label>Diclophenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <arm_group_label>Triamcinolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cystoids macular edema which is diagnosed by OCT and flurocein angiography

          -  5/200 &lt; Visual acuity &lt; 20/50

          -  resistance to routine treatment (oral treatment, periocular injection)

        Exclusion Criteria:

          -  history of retinal disease cause macular edema like diabetes

          -  arterial occlusion

          -  monocular patients

          -  patients candidate for intra-ocular operation

          -  history of glaucoma or ocular hypertension

          -  any cataract that would interfere with OCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>166666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masoud Soheilian, MD</last_name>
      <phone>+98 21 22585952</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>May 4, 2009</last_update_submitted>
  <last_update_submitted_qc>May 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

